X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Eisai presents data on its anti-fractalkine monoclonal antibody E6011

Yuvraj_pawp by Yuvraj_pawp
13th June 2016
in Americas, News

Eisai Co Ltd. announced that interim analyses on the latest data for the world’s first anti-fractalkine monoclonal antibody E6011, discovered by Eisai’s research subsidiary KAN Research Institute Inc. from two respective Phase I/II clinical studies in Crohn’s disease and rheumatoid arthritis (Study 101 and Study 103) showed positive results for safety and tolerability, and exploratory assessment suggested clinical activity for E6011. These data have been presented at a number of recent academic conferences.

 

Study 101 is a multicenter, open-label study to evaluate mainly the safety and tolerability of E6011 in 21 Japanese patients with Crohn’s disease who respond inadequately to conventional therapy which includes anti-tumor necrosis factor (TNF) therapies. The results of Study 101 were presented at Digestive Disease Week 20161 in May.

 

Study 103 is a multicenter, open-label study to evaluate mainly the safety and tolerability of E6011 in 27 Japanese patients with rheumatoid arthritis who respond inadequately to methotrexate or anti-TNF therapy. The results of study 103 were presented at the American College of Rheumatology (ACR) Annual Meeting2 in November 2015, the Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology3 in April 2016 and the Annual European Congress of Rheumatology EULAR 20164in June. Additionally, the presentation on the results of Study 103 was accepted as a late-breaking abstract for the ACR Annual Meeting 2015.

 

Fractalkine is expressed on the surface of vascular endothelial cells in patients with inflammatory diseases including rheumatoid arthritis and inflammatory bowel diseases, and is involved in inflammatory response when bound to fractalkine receptors (CX3CR1) expressed in immune cells. E6011 is an antibody therapy with a novel mechanism of action, and is believed to exhibit an anti-inflammatory effect by suppressing the migration and invasion of CX3CR1-positive immune cells.

Eisai is striving to accelerate the development of E6011 as a key product to contribute to improving the benefit for a greater number of patients and their families.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

1 Matsuoka K, et al., Safety, Tolerability and Efficacy of E6011, Anti-Human Fractalkine Monoclonal Antibody, in the First-Patient Study for Crohn’s Disease, Digestive Disease Week 2016, Poster Number Mo1890.
2 Tanaka Y, et al., Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis. ACR 2015. Late-breaking Abstract Number 13L
3 Tanaka Y, et al., Safety, Pharmacokinetics and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Japanese Patients with Rheumatoid Arthritis. 60th Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology 2016. Poster Number ICW-C15-5.
4 Tanaka Y, et al., Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis. EULAR Annual European Congress of Rheumatology 2016, Poster Number FRI0236
5 Data from the Japan Intractable Disease Information Center: http://www.nanbyou.or.jp/entry/81
6 World Health Organization, Chronic Rheumatic Conditions: http://www.who.int/chp/topics/rheumatic/en.

Tags: America
Previous Post

Sanofi Announces Positive Phase 3 Results For Investigational Titratable Fixed-Ratio

Next Post

Shire to license investigational gastric drug from Pfizer

Related Posts

Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Next Post

Shire to license investigational gastric drug from Pfizer

Latest News

Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In